Breadcrumb

[A17-29] Nivolumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V

Overview

Overview

Commission: Commission awarded on 2017-07-03 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessement  [PDF, 152 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A19-11] Nivolumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A18-53] Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A18-40] Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2017-10-02 Extract of dossier assessement 152 kBPDFdownload file
2017-10-02 Dossier assessment (German version) 478 kBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Extract of dossier assessment

  File-Icon  Nivolumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V [PDF, 152 kB]

Federal Joint Committee (G-BA)

2017-12-21 A G-BA decision was published.

G-BA documents on this decision

Press releases

2018-01-04 Atezolizumab, pembrolizumab, nivolumab in urothelial carcinoma: Studies of direct comparison are useful



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close